Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO® (IC51), in 6 months of follow-up

Vaccine

Volumn 28, Issue 39, 2010, Pages 6463-6469

  Dubischar Kastner, Katrin ^a   Kaltenboeck, Astrid ^a   Klingler, Anton ^b   Jilma, Bernd ^c   Schuller, Elisabeth ^a  

^a INTERCELL AG   (Austria)

^b ASSIGN DATA MANAGEMENT AND BIOSTATISTICS GMBH   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

IC51; IXIARO ; Japanese encephalitis; Local reactions; Systemic adverse events

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIHISTAMINIC AGENT; CORTICOSTEROID; HEPATITIS A VACCINE; IC 51; INACTIVATED VACCINE; IXIARO; JAPANESE ENCEPHALITIS VACCINE; JE-VAX; LANSOPRAZOLE; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUSTRALIA; CANADA; CELL CULTURE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; EUROPE; FATIGUE; FEMALE; FLU LIKE SYNDROME; FLUSHING; FOLLOW UP; HUMAN; HYPERSENSITIVITY; HYPOTENSION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; OCULAR PRURITUS; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; UNITED STATES; URTICARIA; VACCINATION; VERO CELL; VOMITING; WHEEZING; WITHDRAWAL SYNDROME;

ADULT; ANIMALS; CERCOPITHECUS AETHIOPS; CLINICAL TRIALS, PHASE III AS TOPIC; ENCEPHALITIS, JAPANESE; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPANESE ENCEPHALITIS VACCINES; MALE; MIDDLE AGED; VERO CELLS; YOUNG ADULT;

EID: 77956399155     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.040     Document Type: Article

References (22)

1. Burke D.S., Leake C.J. Japanese encephalitis. The arboviruses: epidemiology and ecology 1988, vol. III. CRC Press, Boca Raton, FL, 63-92.
2. World Health Organisation. Health topics: encephalitis, Japanese. Available at [accessed 27.11.09]. http://www.wpro.who.int/health_topics/encephalitis_japanese/.
3. Anderson M.M., Ronne T. Side-effects with Japanese encephalitis vaccine. Lancet 1991, 337:1044.
4. Berg S.W., Mitchell B.S., Hanson R.K., Olafson R.P., Williams R.P., Tueller J.E., et al. Systemic reactions in U.S Marine Corps personnel who received Japanese encephalitis vaccine. Clin Infect Dis 1997, 24:265-266.
5. Plesner A.M., Ronne T. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. Vaccine 1997, 15:1239-1243.
6. Ruff T.A., Eisen D., Fuller A., Kass R. Adverse reactions to Japanese encephalitis vaccine. Lancet 1991, 338:881-882.
7. Sanchez J.L., Hoke C.H., McCowan J., DeFraites R.F., Takafuji E.T., Diniega B.M., et al. Further experience with Japanese encephalitis vaccine. Lancet 1990, 335:972-973.
8. Kamin W., Staubach P., Klär-Hlawatsch B., Erdnüss F., Knuf M. Anaphylaxis after vaccination due to hypersensitivity to gelatin. Klin Padiatr 2006, 218:92-94.
9. Sakaguchi M., Inouye S. IgE sensitization to gelatin: the probable role of gelatin-containing diphtheria-tetanus-acellular pertussis (DTaP) vaccines. Vaccine 2000, 18:2055-2058.
10. Zent O., Arras-Reiter C., Broeker M. Immediate allergic reactions after vaccination-post marketing surveillance review. Eur J Pediatr 2002, 161:21-25.
11. Sakaguchi M., Inouye S. Two patterns of systemic immediate-type reactions to Japanese encephalitis vaccines. Vaccine 1998, 16:68-69.
12. Sakaguchi M., Miyazawa H., Inouye S. Specific IgE and IgG to gelatin in children with systemic cutaneous reactions to Japanese encephalitis vaccines. Allergy 2001, 56:536-539.
13. US Department of Health and Human Services, Centers for Disease Control and Prevention Inactivated Japanese Encephalitis Virus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep (MMWR) 1993, 42:RR-1. Available at: http://www.cdc.gov/mmwr/PDF/rr/rr4201.pdf [accessed 23.11.09].
14. GACVS. Weekly Epidemiological Record No. 28, 2005, 80, 241-8. Available at: [accessed 11.01.08]. http://www.who.int/wer/2005/wer8028.pdf.
15. Tauber E., Kollaritsch H., Korinek M., Rendi-Wagner P., Jilma B., Firbas C., et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, Phase III, randomised controlled trial. Lancet 2007, 370:1847-1853.
16. Tauber E., Kollaritsch H., von Sonnenburg F., Lademann M., Jilma B., Firbas C., et al. Randomized, double-blind, placebo-controlled Phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008, 198:493-499.
17. Schuller E., Klade C.S., Wölfl G., Kaltenböck A., Dewasthaly S., Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 2009, 27:2188-2193.
18. ®1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study. Vaccine 2009, 27:4483-44892.
19. Schuller E., Jilma B., Voicu V., Golor G., Kollaritsch H., Kaltenböck A., et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51: six and 12 month results of a multicenter follow-up Phase 3 study. Vaccine 2008, 26:4382-4386.
20. Dubischar-Kastner K.L., Eder S., Kaltenböck A., Klade C., Schuller E., Wölfl G. Long term immunity following vaccination with the inactivated Japanese encephalitis vaccine IC51 and immune response to a booster dose. Proceedings of the 11th conference of the International Society of Travel Medicine 2009.
21. Newcombe R.G., Altman D.G. Proportions and their differences. Statistics with confidence. Confidence intervals and statistical guidelines 2007, 45-56. BMJ Books, Bristol. D.G. Altman, D. Machin, T.N. Bryant, M.J. Gardner (Eds.).
22. Kaltenböck A., Dubischar-Kastner K., Schuller E., Datla M., Klade C.S., Kishore T.S.A. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010, 28:834-839.